Computed tomography textural analysis for the differentiation of chronic lymphocytic leukemia and diffuse large B cell lymphoma of Richter syndrome.


Journal

European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 14 03 2019
accepted: 28 05 2019
revised: 11 05 2019
pubmed: 27 6 2019
medline: 6 2 2020
entrez: 26 6 2019
Statut: ppublish

Résumé

To test the hypothesis that both indolent and aggressive chronic lymphocytic leukemia (CLL) can be differentiated from diffuse large B cell lymphoma (DLBCL) of Richter syndrome (RS) by CT texture analysis (CTTA) of involved lymph nodes. We retrospectively included 52 patients with indolent CLL (26/52), aggressive CLL (8/52), and DLBCL of RS (18/52), who underwent standardized contrast-enhanced CT. In main lymphoma tissue, VOIs were generated from which CTTA features including first-, second-, and higher-order textural features were extracted. CTTA features were compared between the entire CLL group, the indolent CLL subtype, the aggressive CLL subtype, and DLBCL using a Kruskal-Wallis test. All p values were adjusted after the Bonferroni correction. ROC analyses for significant CTTA features were performed to determine cut-off values for differentiation between the groups. Compared with DLBCL of RS, CTTA of the entire CLL group showed significant differences of entropy heterogeneity (p < 0.001), mean intensity (p < 0.001), mean average (p = 0.02), and number non-uniformity gray-level dependence matrix (NGLDM) (p = 0.03). Indolent CLL significantly differed for entropy (p < 0.001), uniformity of heterogeneity (p = 0.02), mean intensity (p < 0.001), and mean average (p = 0.01). Aggressive CLL showed significant differences in mean intensity (p = 0.04). For differentiation between CLL and DLBCL of RS, cut-off values for mean intensity and entropy of heterogeneity were defined (e.g., 6.63 for entropy heterogeneity [aggressive CLL vs. DLBCL]; sensitivity 0.78; specificity 0.63). CTTA features of ultrastructure and vascularization significantly differ in CLL compared with that in DLBCL of Richter syndrome, allowing complementary to visual features for noninvasive differentiation by contrast-enhanced CT. • Richter transformation of CLL into DLBCL results in structural changes in lymph node architecture and vascularization that can be detected by CTTA. • First-order CT textural features including intensity and heterogeneity significantly differ between both indolent CLL and aggressive CLL and DLBCL of Richter syndrome. • CT texture analysis allows for noninvasive detection of Richter syndrome which is of prognostic value.

Identifiants

pubmed: 31236702
doi: 10.1007/s00330-019-06291-9
pii: 10.1007/s00330-019-06291-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6911-6921

Références

Radiology. 2011 Oct;261(1):165-71
pubmed: 21813743
Eur Radiol. 2012 Apr;22(4):796-802
pubmed: 22086561
J Nucl Med. 2006 Aug;47(8):1267-73
pubmed: 16883004
Blood. 2011 Mar 24;117(12):3391-401
pubmed: 21266718
Am J Hematol. 2017 Sep;92(9):946-965
pubmed: 28782884
Radiology. 2013 Jan;266(1):177-84
pubmed: 23151829
J Comput Assist Tomogr. 2001 May-Jun;25(3):482-6
pubmed: 11351202
Eur Radiol. 2018 Apr;28(4):1520-1528
pubmed: 29164382
Ann Oncol. 2009 Mar;20(3):413-24
pubmed: 19088170
Blood. 1990 Apr 1;75(7):1414-21
pubmed: 2180492
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
Cancer Imaging. 2013 Sep 23;13(3):400-6
pubmed: 24061266
Curr Treat Options Oncol. 2017 Jul;18(7):45
pubmed: 28670664
Mayo Clin Proc. 2012 Jun;87(6):571-80
pubmed: 22677077
Curr Hematol Malig Rep. 2016 Feb;11(1):43-51
pubmed: 26830086
Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):596-604
pubmed: 24469258
AJR Am J Roentgenol. 2012 Jun;198(6):1239-46
pubmed: 22623535
Cancer Imaging. 2013 Mar 26;13:140-9
pubmed: 23545171
Cancer. 2006 Sep 15;107(6):1294-302
pubmed: 16902984
Eur Radiol. 2017 Mar;27(3):1012-1020
pubmed: 27380902
Am J Surg Pathol. 2007 Oct;31(10):1605-14
pubmed: 17895764
Oncology (Williston Park). 2012 Dec;26(12):1146-52
pubmed: 23413591
Clin Radiol. 2012 Feb;67(2):157-64
pubmed: 21943720
Eur J Radiol. 2016 Jan;85(1):304-309
pubmed: 26515992
Leuk Lymphoma. 2014 Feb;55(2):233-4
pubmed: 23915194
Dis Esophagus. 2015 Feb-Mar;28(2):172-9
pubmed: 24460831
Ann Hematol. 2017 Jan;96(1):17-23
pubmed: 27677489
Leuk Lymphoma. 2014 Feb;55(2):314-9
pubmed: 23656196
Cancer. 1981 Jul 1;48(1):198-206
pubmed: 7237385
Haematologica. 2011 Jul;96(7):996-1001
pubmed: 21546504
Histopathology. 2016 Dec;69(6):1066-1076
pubmed: 27345622
Abdom Radiol (NY). 2017 May;42(5):1485-1492
pubmed: 28025654
Nucl Med Commun. 2017 Jul;38(7):563-576
pubmed: 28570287
Radiographics. 2017 Sep-Oct;37(5):1483-1503
pubmed: 28898189
Med J Armed Forces India. 2009 Oct;65(4):375-7
pubmed: 27408297
Radiology. 2013 Dec;269(3):801-9
pubmed: 23912620
Ann Nucl Med. 2011 Oct;25(8):536-46
pubmed: 21674240
Rofo. 2014 Jan;186(1):79-80
pubmed: 23975876

Auteurs

C P Reinert (CP)

Department of Diagnostic and Interventional Radiology, University Hospital Tübingen, Hoppe-Seyler-Str.3, 72076, Tübingen, Germany. christian.reinert@med.uni-tuebingen.de.

B Federmann (B)

Department of Pathology and Neuropathology, University Hospital Tübingen, Liebermeisterstraße 8, 72076, Tübingen, Germany.

J Hofmann (J)

Department of Diagnostic and Interventional Radiology, University Hospital Tübingen, Hoppe-Seyler-Str.3, 72076, Tübingen, Germany.

H Bösmüller (H)

Department of Pathology and Neuropathology, University Hospital Tübingen, Liebermeisterstraße 8, 72076, Tübingen, Germany.

S Wirths (S)

Department of Hematology and Oncology, University Hospital Tübingen, Otfried-Müller-Str. 10, 72076, Tübingen, Germany.

J Fritz (J)

Russell H. Morgan Department of Radiology and Radiological, Johns Hopkins University School of Medicine, Science, 601 N. Caroline Street, JHOC 3142, Baltimore, MD, 21287, USA.

M Horger (M)

Department of Diagnostic and Interventional Radiology, University Hospital Tübingen, Hoppe-Seyler-Str.3, 72076, Tübingen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH